Concordance between substance P levels and antiemetic guidelines

Higa, Gerald M.; Auber, Miklos; Altaha, Ramin; Hobbs, Gregory J.

doi:10.1200/jco.2008.26.15_suppl.9552

Cited by 9 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regards the Substance P, a neuromodulator belonging to a group of neurokinins that are widely distributed in the CNS (Datar et al, 2004; Mantyh, 2002), it has been reported its involvement in regulation and generation of many physiological and pathophysiological conditions (King and Barr, 2003; Higa et al, 2009; Jiménez‐Corral et al, 2006; Mauborgn et al, 1983) including breathing acceleration in hypoxic events (Lagercrantz et al, 1991; Hedner et al, 1985; Lavezzi et al, 2011b). This function in particular is mediated by Substance P‐binding to the NK1 receptor and subsequent transport across the BBB with its release in periphery (Chappa et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Vulnerability of fourth ventricle choroid plexus in sudden unexplained fetal and infant death syndromes related to smoking mothers

Lavezzi

Matturri

Corno

et al. 2013

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

The human choroid plexuses in the ventricular system represent the main source of cerebrospinal fluid secretion and constitute a major barrier interface that controls the brain's environment. The present study focused on the choroid plexus of the fourth ventricle, the main cavity of the brainstem containing important nuclei and/or structures mediating autonomic vital functions. In serial sections of 84 brainstems of subjects aged from 17 gestational weeks to 8 postnatal months of life, the deaths due to both known and unknown causes, we examined the cytoarchitecture and the developmental steps of the fourth ventricle choroid plexus to determine whether this structure shows morphological and/or functional alterations in unexplained perinatal deaths (Sudden Infant Death Syndrome and Sudden Intrauterine Unexplained Death Syndrome). High incidence of histological and immunohistochemical alterations (prevalence of epithelial dark cells, the presence of cystic cells in the stroma, decreased number of blood capillaries, hyperexpression of Substance P and apoptosis) were prevalently observed in unexplained death victims (p<0.05 vs. controls). A significant correlation was found between maternal smoking in pregnancy and choroidal neuropathological parameters (p<0.01). This work underscores the negative effects of prenatal exposure to nicotine on the development of the autonomic nervous system, and in particular of the fourth ventricle choroid plexus that is a very vulnerable structure in the developing CSF-brain system.

show abstract

Section: Discussionmentioning

confidence: 99%

Vulnerability of fourth ventricle choroid plexus in sudden unexplained fetal and infant death syndromes related to smoking mothers

Lavezzi

Matturri

Corno

et al. 2013

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

show abstract

“…34 Accumulating evidence suggests that delayed CINV is largely associated with the activation of NK-1 receptors by SP. 27,40,61 However, multiple overlapping neurotransmitters (e.g., dopamine), acting in the peripheral and central nervous systems, may also be involved in acute and delayed CINV. 62 …”

Section: Pathophysiology Of Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Janelsins¹,

Tejani²,

Kamen³

et al. 2013

Expert Opinion on Pharmacotherapy

134

110

View full text Add to dashboard Cite

Introduction Nausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy. Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting. Areas Covered The purpose of this article is to provide an overview of the patho-psychophysiology of chemotherapy-induced nausea and vomiting, the recommended guidelines for treatment, current agents in late-stage clinical trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting. Expert Opinion Despite advances in pharmaceutical and behavioral therapies, and the provision of standard clinical guidelines for effectively managing chemotherapy-induced nausea and vomiting (CINV), patients continue to experience CINV. Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting (ANV) remains an important, unmet need among cancer patients. It is critical to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms, and delayed symptoms.

show abstract

“…The investigational arm should maximize coverage for delayed nausea and vomiting by using two doses of palonosetron combined with an NK1 antagonist given for multiple days, as in the Bubalo studies. Initial investigations suggest that substance P levels continue to rise after highly emetogenic chemotherapy; 24,32 daily doses of an NK1 receptor antagonist through day 4 following the stem cell infusion may help to counteract the delayed effects of the events occurring up to the day of the stem cell infusion, as in the Bubalo studies. 20,21 Minimizing CINV should be a reasonable goal for those receiving these highly emetogenic therapies.…”

Section: The Need For Further Trialsmentioning

confidence: 99%

Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens

Trigg

Inverso

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Stem cell transplantation, using high-dose chemotherapy with or without TBI, is usually associated with significant nausea and vomiting. A variety of antiemetic regimens have been studied to control nausea and vomiting associated with the preparative therapy phase of SCT. We review the most significant studies and highlight the limitations of many of these studies. In addition, we review the few studies with the use of aprepitant as an antiemetic in combination with a 5HT 3 antagonist and a steroid. The American Society of Clinical Oncology guideline for antiemetic use for treatment regimens that are highly emetogenic is reviewed regarding recommendations for SCT preparative regimens. On the basis of this review of published data, we recommend the basic outline for an effective antiemetic investigational approach to the study and to the control of nausea and vomiting during the preparative phase of treatment for SCT.

show abstract

Concordance between substance P levels and antiemetic guidelines

Cited by 9 publications

References 0 publications

Vulnerability of fourth ventricle choroid plexus in sudden unexplained fetal and infant death syndromes related to smoking mothers

Vulnerability of fourth ventricle choroid plexus in sudden unexplained fetal and infant death syndromes related to smoking mothers

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens

Contact Info

Product

Resources

About